Press releases

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis...

Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced...

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025.

MARLBOROUGH, Mass., Aug. 6, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced data from a recent national survey of 2,000 U.S. women between the ages of 30 and 65, which examined...

"This was another excellent quarter, marked by exceptional top-line performance,” said chairman and CEO Mike Mahoney

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23,...

Boston Scientific will participate in two upcoming investor conferences in May 2025. A live webcast and replay will be available for each event. Read more.

Trial achieves positive results in the treatment of persistent atrial fibrillation.

After 30 successful years with Boston Scientific, Dan will work closely with CFO successor Jon Monson to ensure a smooth transition.